78
Participants
Start Date
December 31, 2009
Primary Completion Date
July 31, 2013
Study Completion Date
October 31, 2014
Amrubicin
"Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m\^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m\^2; DL3 - 110mg/m\^2; and DL4 - 120mg/m\^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
Berks Hematology Oncology Associates, West Reading
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
Peninsula Cancer Institute, Newport News
Northeast Georgia Medical Center, Gainesville
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Baptist Hospital East, Louisville
Norton Cancer Institute, Louisville
Oncology Hematology Care, Inc, Cincinnati
Grand Rapids Clinical Oncology Program, Grand Rapids
Nebraska Methodist Cancer Center, Omaha
Hematology Oncology Clinic, LLP, Baton Rouge
NEA Baptist Clinic, Jonesboro
The Center for Cancer and Blood Disorders, Fort Worth
Portsmouth Regional Hospital, Portsmouth
Collaborators (1)
Celgene
INDUSTRY
SCRI Development Innovations, LLC
OTHER